RE:RE:Expectations MrMugsy wrote: Haven't been paying attention to this lately but - investment in Singlar G also took another hit as the stock likely bottomed in the last quarter and we will probably take an adjustment hit. Highly doubt there were any investment wins in the last quarter as the general markets were rocked.
Might just be the end of that Genome saga as Revenues slowly mute out that noise.
IMO.
Well, fortunately that situation has gotten a little better. From the latest quarterly report:
For example, through its strategic fund investment, Knight has recorded life to date unrealized gains on investment in SGS and REPL, refer to Section 10 for further information. However, as at May 10, 2022, SGS’s share price closed at USD 3.38 and USD 14.48 respectively. Should the share price of SGS and REPL remain at this level the Company would record an unrealized loss of approximately $4,151 [USD 3,189] and $1,697 [USD 1,304] respectively. The Company’s Board of Directors regularly reviews and approves equity investment decisions.
Between May 10th and June 30th, SGS went up 13% and REPL went up 20%. Therefore at least a part of those unrealized losses were recovered before the quarter ended.
Also, since the end of Q2, SGS is +13% and REPL is +17%. :)